other material
confidence high
sentiment negative
materiality 0.65
Aeglea recasts FY2022 financials for 1-for-25 reverse split; going concern warning persists
Spyre Therapeutics, Inc.
- 1-for-25 reverse stock split effective Sept 8, 2023; authorized shares cut from 500M to 20M.
- Recast FY2022 net loss $83.8M ($24.86/share) on total revenue of $2.3M.
- Accumulated deficit $425.6M as of Dec 31, 2022; cash & securities $57.3M.
- Substantial doubt about going concern; cash expected to fund only into Q4 2023.
- Auditor's opinion includes going concern emphasis paragraph.